Subtopic Deep Dive

Patent Ductus Arteriosus and Bronchopulmonary Dysplasia
Research Guide

What is Patent Ductus Arteriosus and Bronchopulmonary Dysplasia?

Patent Ductus Arteriosus (PDA) and Bronchopulmonary Dysplasia (BPD) research examines the hemodynamic association between persistent PDA in preterm infants and increased BPD risk, evaluating treatment impacts on lung outcomes.

Persistent PDA in extremely preterm infants correlates with higher BPD incidence due to altered pulmonary blood flow and ventilation requirements (Hamrick et al., 2020, 266 citations). Studies compare pharmacologic closures like indomethacin, ibuprofen, and paracetamol against expectant management, with over 2,000 citations across key trials. Longitudinal data link PDA treatments to neurodevelopmental effects and brain volume changes (Lemmers et al., 2016, 78 citations).

15
Curated Papers
3
Key Challenges

Why It Matters

Determining PDA's causal role in BPD guides preterm management, reducing mechanical ventilation and oxygen exposure needs (Hundscheid et al., 2022, 163 citations). Conservative approaches like expectant management show noninferiority to early ibuprofen for BPD, necrotizing enterocolitis, or death (Hundscheid et al., 2022). Surgical ligation risks post-closure physiology shifts affecting lung and brain perfusion (El‐Khuffash et al., 2013, 84 citations). These insights lower long-term morbidities in neonatal intensive care, impacting ~10% of very preterm infants annually.

Key Research Challenges

PDA-BPD Causality Evidence

Distinguishing PDA's direct contribution to BPD from prematurity confounders remains unresolved despite cohort studies (Bose and Laughon, 2007, 198 citations). Trials show pharmacologic closure reduces PDA but not BPD or mortality (Fowlie et al., 2010, 481 citations). Observational biases complicate randomized designs in fragile preterm populations.

Optimal Treatment Timing

Expectant management versus early closure debates persist, with noninferiority for BPD in recent trials (Hundscheid et al., 2022, 163 citations). Natural PDA evolution shows frequent spontaneous closure without outcome benefits from intervention (Rolland et al., 2014, 111 citations). Balancing risks of prolonged shunting against treatment toxicities challenges protocols.

Neurodevelopmental Impacts

PDA ligation alters cerebral perfusion, linking to reduced brain volume in preterm infants (Lemmers et al., 2016, 78 citations). Post-closure hemodynamic shifts increase intraventricular hemorrhage risks (Fowlie et al., 2010). Long-term cognitive outcomes require extended cohorts beyond current 36-week assessments.

Essential Papers

1.

Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants

Peter W Fowlie, Peter G. Davis, William McGuire · 2010 · Cochrane Database of Systematic Reviews · 481 citations

Prophylactic indomethacin has short-term benefits for preterm infants including a reduction in the incidence of symptomatic PDA, PDA surgical ligation, and severe intraventricular haemorrhage. Howe...

2.

Patent Ductus Arteriosus of the Preterm Infant

Shannon E. G. Hamrick, Hannes Sallmon, Allison T. Rose et al. · 2020 · PEDIATRICS · 266 citations

Postnatal ductal closure is stimulated by rising oxygen tension and withdrawal of vasodilatory mediators (prostaglandins, nitric oxide, adenosine) and by vasoconstrictors (endothelin-1, catecholami...

3.

Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomised controlled trial

Paola Lago, Tiziana Bettiol, Sabrina Salvadori et al. · 2002 · European Journal of Pediatrics · 205 citations

4.

Patent ductus arteriosus: lack of evidence for common treatments

Cameron Bose, M. M Laughon · 2007 · Archives of Disease in Childhood Fetal & Neonatal · 198 citations

Patent ductus arteriosus (PDA) is a common diagnosis among extremely premature infants, especially in those with lung disease. Treatments are often used to close the PDA. Despite nearly three decad...

5.

Comparison of Oral Paracetamol versus Ibuprofen in Premature Infants with Patent Ductus Arteriosus: A Randomized Controlled Trial

Dan Dang, Dongxuan Wang, Chuan Zhang et al. · 2013 · PLoS ONE · 174 citations

ChiCTR.org ChiCTR-TRC-12002177.

6.

Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus

Tim Hundscheid, Wes Onland, Elisabeth M. W. Kooi et al. · 2022 · New England Journal of Medicine · 163 citations

Expectant management for PDA in extremely premature infants was noninferior to early ibuprofen treatment with respect to necrotizing enterocolitis, bronchopulmonary dysplasia, or death at 36 weeks'...

7.

Natural evolution of patent ductus arteriosus in the extremely preterm infant

Audrey Rolland, Shivani Shankar‐Aguilera, Douty Diomandé et al. · 2014 · Archives of Disease in Childhood Fetal & Neonatal · 111 citations

Objective The persistence of the patent ductus arteriosus (PDA) is frequently encountered in very preterm infants. Neither preventive nor curative treatments of PDA have been shown to improve the o...

Reading Guide

Foundational Papers

Start with Fowlie et al. (2010, 481 citations) for indomethacin effects on PDA and intraventricular hemorrhage; Bose and Laughon (2007, 198 citations) critiques treatment evidence gaps; Lago et al. (2002, 205 citations) compares ibuprofen to indomethacin safety.

Recent Advances

Hundscheid et al. (2022, 163 citations) demonstrates expectant management noninferiority for BPD; Hamrick et al. (2020, 266 citations) details ductal physiology; Lemmers et al. (2016, 78 citations) links PDA to brain volume loss.

Core Methods

Randomized controlled trials (ibuprofen vs indomethacin, paracetamol); expectant management cohorts; physiologic modeling of shunting; brain MRI volumetrics post-ligation.

How PapersFlow Helps You Research Patent Ductus Arteriosus and Bronchopulmonary Dysplasia

Discover & Search

Research Agent uses searchPapers and citationGraph on 'PDA bronchopulmonary dysplasia preterm' to map 250M+ OpenAlex papers, revealing clusters around Hamrick et al. (2020) with 266 citations linking ductal physiology to BPD. exaSearch uncovers hidden reviews; findSimilarPapers expands to Hundscheid et al. (2022) for expectant management data.

Analyze & Verify

Analysis Agent applies readPaperContent to extract BPD outcomes from Fowlie et al. (2010), then verifyResponse with CoVe checks claims against cohorts. runPythonAnalysis processes citation metadata for GRADE grading of indomethacin trials (moderate evidence for PDA reduction, low for BPD). Statistical verification flags Bose and Laughon (2007) evidence gaps.

Synthesize & Write

Synthesis Agent detects gaps in PDA-BPD causality via contradiction flagging across Rolland et al. (2014) and Hundscheid et al. (2022); Writing Agent uses latexEditText, latexSyncCitations for trial comparison tables, and latexCompile for publication-ready reviews. exportMermaid visualizes treatment outcome flows.

Use Cases

"Run meta-analysis on PDA treatments and BPD rates from top trials"

Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas meta-analysis on Fowlie 2010, Hundscheid 2022 BPD odds ratios) → Synthesis Agent → exportCsv of pooled risks.

"Draft LaTeX review comparing ibuprofen vs expectant PDA management"

Research Agent → citationGraph (Lago 2002, Hundscheid 2022) → Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations + latexCompile → PDF with BPD outcome tables.

"Find code for modeling PDA shunt effects on lung perfusion"

Research Agent → paperExtractUrls (Hamrick 2020) → Code Discovery → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis sandbox tests hemodynamic simulation scripts.

Automated Workflows

Deep Research workflow conducts systematic review: searchPapers (PDA BPD preterm) → 50+ papers → DeepScan (7-step CoVe analysis with GRADE on Fowlie 2010) → structured BPD causality report. Theorizer generates hypotheses on ligation physiology from El‐Khuffash 2013 and Lemmers 2016, chaining citationGraph to Deep Research for validation.

Frequently Asked Questions

What defines PDA-BPD association?

Persistent PDA in preterm infants increases left-to-right shunting, elevating pulmonary pressures and BPD risk via ventilation needs (Hamrick et al., 2020).

What are main PDA treatment methods?

Methods include indomethacin, ibuprofen, paracetamol, ligation, or expectant management; prophylactic indomethacin reduces PDA incidence but not BPD (Fowlie et al., 2010, 481 citations).

What are key papers?

Fowlie et al. (2010, 481 citations) on indomethacin; Hundscheid et al. (2022, 163 citations) showing expectant management noninferiority for BPD.

What open problems exist?

Unresolved causality between PDA and BPD, optimal closure timing, and long-term neurodevelopmental effects post-ligation (Bose and Laughon, 2007; Lemmers et al., 2016).

Research Cardiovascular Conditions and Treatments with AI

PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:

See how researchers in Health & Medicine use PapersFlow

Field-specific workflows, example queries, and use cases.

Health & Medicine Guide

Start Researching Patent Ductus Arteriosus and Bronchopulmonary Dysplasia with AI

Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.

See how PapersFlow works for Medicine researchers